DR JOSEPH SAMUEL DOYLE (Orcid ID : 0000-0001-7198-0833)

Article type : Original Scientific Paper

Treatment access is only the first step to hepatitis C elimination: experience of universal antiviral treatment access in Australia

Authors:

Joseph S. Doyle^{1,2}, Nick Scott^{2,3}, Rachel Sacks-Davis,² Alisa E. Pedrana^{2,3}, Alexander J. Thompson^{4,5}, Margaret E. Hellard^{1,2,3} on behalf of the Eliminate Hepatitis C Partnership

Affiliations

¹Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Australia;

²Centre for Population Health, Burnet Institute, Melbourne, Australia;

³School of Population Health and Preventive Medicine, Monash University, Melbourne, Australia;

⁴Department of Gastroenterology, St Vincent's Hospital Melbourne, Australia;

⁵Department of Medicine, University of Melbourne, Australia.

Author contact details:

Dr Joseph S. Doyle PhD FRACP

The Alfred & Monash University, Department of Infectious Diseases, 85 Commercial Road,
Melbourne VIC 3004

Email: joseph.doyle@monash.edu;

Telephone: +61 3 8506 2324; Fax: +61 3 9282 2100.

Abstract word count: 249

Word count: 3229

Table count: 1

Figure count: 3

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/APT.15210](https://doi.org/10.1111/APT.15210)

This article is protected by copyright. All rights reserved

Keywords: Hepatitis C; elimination; treatment; universal access

Running Header: Pathways to hepatitis C elimination

ACKNOWLEDGEMENTS

Eliminate Hepatitis C Partnership investigators

Prof Margaret Hellard, Prof Alex Thompson, Dr Joseph Doyle, Prof Paul Dietze, Prof Emma McBryde, Prof William Sievert, Prof Mark Stoove, Dr Peter Higgs, Dr Denis Petrie, Prof Peter Vickerman.

Author's contributions

Guarantor: Dr Joseph Doyle. Study design and concept: all authors. Data analysis and interpretation: all authors. Manuscript preparation and critical revision: all authors. All authors approved the final submitted version.

SUMMARY

Background: Global targets to eliminate hepatitis C (HCV) might be met by sustained treatment uptake. **Aims:** We describe factors facilitating HCV treatment uptake and potential challenges to sustaining treatment levels after universal access to direct acting antivirals (DAA) across Australia.

Methods: We analysed national Pharmaceutical Benefits Scheme data to determine the number of DAA prescriptions commenced before and after universal access from March 2016 to June 2017. We inferred facilitators and barriers to treatment uptake, and challenges that will prevent local and global jurisdictions reaching elimination targets.

Results: In 2016, 32,887 individuals (14% of people living with HCV in Australia) commenced HCV DAA treatment, and 34,952 (15%) individuals commenced treatment in the first year of universal access. Treatment uptake peaked at 13,109 DAA commencements per quarter immediately after universal access, but more than halved (to 5,320 in 2017Q2) within 12 months. General practitioners have written 24% of all prescriptions but with a significantly increased proportion over time (9% in 2016Q1 to 37% in 2017Q2). In contrast, hepatology or infectious diseases specialists' have written declining share from 74% to 38% during the same period. General practitioners provided a greater proportion (47%) of care in regional/remote areas than major cities.

Conclusions: Broad treatment access led to rapid initial increases in treatment uptake, but this uptake has not been sustained. Our results suggest achieving global elimination targets requires more than treatment availability: people with HCV need easy access to testing and linkage to care in community settings employing a diverse prescriber base.

1 INTRODUCTION

2 Chronic hepatitis C virus (HCV) infection affects approximately 71 million people globally,¹
 3 and an estimated 400,000 people die each year from hepatitis C-related liver diseases.² The
 4 new era of direct-acting antiviral (DAA) treatment has revolutionised hepatitis C care, with
 5 cure rates over 90% and short, well tolerated courses of tablets, providing a once in a
 6 generation opportunity to eliminate hepatitis C as a global public health threat. Recent World
 7 Health Organization targets aim to reduce new hepatitis C infections by 80%, and reduce
 8 deaths due to hepatitis C by 65% by 2030. However, success in elimination is contingent
 9 upon increasing testing, diagnosis, linkage to care, and low cost treatment enabling high-
 10 levels of treatment uptake and cure. Curing large numbers of people with hepatitis C
 11 infection reduces hepatitis C prevalence; in particular, curing individuals still engaged in
 12 transmission risk practices delivers an additive treatment-as-prevention impact by reducing
 13 the pool of hepatitis C infection within key populations, reducing disease incidence.

14
 15 In Australia approximately 230,000 people were estimated to live with chronic hepatitis C in
 16 2015, and costs of the hepatitis C burden without treatment was estimated at over AU\$2.43
 17 billion,³ with the majority of infection occurring in people with current or past injecting drug
 18 use.⁴ In 2015, there were 10,000 newly diagnosed cases of hepatitis C in Australia,⁵ with
 19 prevalence among people who inject drugs (PWID) around 50% and an estimated annual
 20 hepatitis C incidence of around 7-8/100 person years among Australian PWID.⁵⁻⁷

21
 22 Modelling suggests that elimination targets will be achieved fastest by rapidly scaling up
 23 highly effective treatments that particularly target high-risk individuals.^{3,8,9} In countries such
 24 as Australia where the epidemic is driven by injecting drug use, relatively small increases in
 25 the percentage of PWID treated annually (from 1% at 2015 levels to 12% after DAA access)
 26 is predicted to reduce hepatitis C incidence by over 80% in the next decade.⁸⁻¹³ [11,12,25-28].
 27 To meet global incidence targets, in Australia this translates into approximately 4,700
 28 treatment courses that need to be delivered to high-risk individuals annually for the next
 29 decade.¹³ In addition, modelling demonstrates that to meet global mortality targets most
 30 quickly, an additional 5,300 treatment courses per annum need to be delivered to those with
 31 advanced liver disease over the first five years.¹³ Crucially, treatment scale up needs to be
 32 *sustained* and *inclusive* of PWID who have been traditionally harder to engage in care. This
 33 needs to be coupled with scale-up of prevention initiatives including needle and syringe
 34 programs (NSP) and opioid substitution therapy (OST). With cost-effectiveness models

1 showing that treating hepatitis C among PWID is only modestly more expensive than treating
 2 non-injectors,¹⁴ the pathway to elimination through broad treatment access appears feasible.

3
 4 March 2016 was a watershed moment in Australia: these new highly-effective treatments
 5 became available for all people living with hepatitis C under the Pharmaceutical Benefits
 6 Scheme (PBS) at a cost of approximately US\$800 million over four years. The PBS
 7 subsidises the cost of medicines after they have been licenced for use in Australia. To receive
 8 government subsidy, a new medication must undergo expert review for clinical and cost
 9 effectiveness. The cost of most medicines to all Australian citizens and permanent residents is
 10 capped at US\$30 per month of treatment, or US\$5 per month for people receiving low
 11 income welfare benefits. The final price paid by government for a medication often remains
 12 confidential. Due to the high price of hepatitis C medications initially, the cost to the
 13 Australian government for hepatitis C treatment was capped at approximately US\$200
 14 million annually under a confidential cost sharing arrangement; any excess cost due to large
 15 volume of prescriptions is borne by drug manufacturers. In addition, Australia has universal
 16 access to treatments, meaning there are no restrictions on who has access to treatment nor the
 17 numbers of times an individual can be treated. National guidelines recommend treatment for
 18 everyone living with hepatitis C infection, including PWID and prisoners.¹⁵ Given the price
 19 of DAAs and universal nature of the PBS, government data systems capture virtually all
 20 hepatitis C prescriptions.

21
 22 With a largely universal, publicly funded, health care and insurance system, the effect of
 23 these policy changes is that Australia has some of the key ingredients needed to eliminate
 24 hepatitis C as a public health threat over the next decade.¹⁶ Australia is one of a few countries
 25 globally on target in this quest.¹⁷ This elimination strategy will not be successful unless we
 26 treat large numbers of people at ongoing risk of hepatitis C transmission, including PWID,
 27 prisoners and HIV-coinfected gay and bisexual men.

28
 29 Using the early experience of a country such as Australia, with a unified approach to
 30 treatment as a case study, factors facilitating and impeding high rates of treatment uptake are
 31 already evident. We aim to describe facilitators to hepatitis C treatment uptake after one year
 32 of universal access to DAAs across Australia, and potential barriers to sustaining up
 33 treatment uptake in future.

34 35 **METHODS**

We analysed PBS data to determine the number of prescriptions initiated from January 2013 to July 2017, which includes the first year of unrestricted DAA access (March 2016 – March 2017) as well as previous interferon-based treatment uptake. Based on the first dispensed prescription of each treatment course, we extracted data on number of prescriptions over time, treatment regimen, geographic location and provider type (general practitioner, gastroenterology/infectious diseases specialist, addiction/sexual health specialists and other medical practitioner prescribers).

Treatment commencement was defined as the first medication dispensing date. Date of treatment commencement is recorded as when the PBS record the prescription being dispensed which may be delayed by days or weeks. We obtained commencement by three-month (quarterly) periods. Treatment regimen was categorised by pegylated-interferon-based or any available interferon-free DAA agent, which includes sofosbuvir, daclatasvir, sofosbuvir/ledipasvir fixed dose, grazeprevir/elbasvir fixed dose, or ombitasvir/paritaprevir/dasabuvir/ritonavir fixed dose, with or without ribavirin.

PBS aggregates data when five or fewer individuals have the same prescription, provider and location to protect against potentially identifying participants based on their treatment characteristics. To calculate number of treatment courses, any field with under six (but not zero) individuals was assumed to represent three individuals, leading to an average estimated error of one percent and maximum of three percent error in total treatment numbers.

Geographic location was coded according to Statistical Area 3 (SA3), a geographical unit defined by the Australian Bureau of Statistics.¹⁸ Australia has 338 SA3s, which each have a population of approximately 30,000 to 130,000 people. Remoteness Area classifications (major city, inner regional, outer regional, remote, very remote) are defined in Australia for smaller geographical units than SA3s, and population-weighted averages from each of the smaller geographical areas were used to create a remoteness area classification for each of the SA3s, and hence for where treatments were initiated.

RESULTS

Since subsidized DAA access in March 2016 until June 2017, 43,382 courses of therapy have been commenced; 32,877 courses commenced in 2016 (10 months of access), and 39,062 courses were commenced in the first four full quarters (after 13 months of access) (Table 1 and Supplementary Figure 1). Prescriptions peaked in the first three months after PBS listing at 13,109 treatment courses per quarter; treatment commencement has declined each

subsequent quarter to 5,320 prescriptions (63% decline since the peak commencement) up to end of June 2017. In the pegylated-interferon-based era (prior to April 2013) and first generation DAA era (2013-2015) a maximum of 2,185 individuals commenced treatment per quarter (in 2013Q3).

Following registration of interferon-free DAAs but prior to government subsidy, treatment initiation dropped substantially (Figure 1). There was a nadir of 361 individuals commencing treatment in the final quarter of 2015.

Prior to interferon-free DAA treatment, viral hepatitis specialists provided nearly all treatment as required by funding rules at the time; general practitioners were required to complete additional training to initiate interferon prior to 2016. Since interferon-free DAA treatment, hepatologists and infectious diseases physicians have accounted for the bulk of prescriptions (54%, Table 1). In the first quarter of DAA access (2016 Q2), 63% of prescriptions were prescribed by hepatologist/infectious disease specialists; 16% by sexual health or addiction medicine specialists, 16% by general practitioners, and remaining 5% by other medical practitioners (Table 1). Since then, the proportion of prescriptions written by hepatologists/infectious diseases specialists has declined (to 38% in 2017 Q2) while share of prescription written by general practitioners' had increased (to 37% 2017 Q2). Nevertheless, despite a shift in the share of prescriptions by practitioner type, the number of general practitioner prescriptions has remaining static over time; all other prescribers have written fewer prescriptions per quarter (Figure 2).

Most individuals received interferon-free DAA treatment from prescribers in major cities (78%) or inner regional areas (16%), which includes outer urban areas adjacent to cities. This corresponds to where 92% of the Australian population reside. Treatment was commenced in outer regional areas and remote areas for 6%, where 7% of the population reside. Fewer than 0.5% of all initiations were identified in very remote geographic areas which have limited prescriber and pharmacy services (Figure 3). An increasing proportion of prescriptions are commenced outside of major cities and regions over time, from 19% in 2016 Q1, to 26% in 2017 Q2. General practitioners provided an increasing share of hepatitis C treatment outside major cities: 50% of regional and 86% of remote prescriptions were GP initiated in 2017 Q2, although absolute treatment numbers prescribed by general practitioners remained stable over time.

Interferon-free DAA treatment commencements by state was approximately in proportion to population distribution: 33% in New South Wales, 27% in Victoria, 20% in Queensland, 6% in South Australia, 8% in Western Australia, 2% in Tasmania, 1% in Northern Territory, 2% in Australian Capital Territory.

DISCUSSION

Access to interferon-free DAAs dramatically increased the number of people undergoing treatment in Australia. However, despite Australia's health system supporting broad access at a relatively low cost to individual patients, and high diagnosis rates prior to the introduction of DAAs,¹⁹ Australia has not sustained high treatment uptake. If Australia and other countries globally are to achieve the WHO elimination goals, the reasons for this fall in treatment uptake need to be better understood. Our work suggests key factors to be considered include engaging and linking individuals living with hepatitis C in care, and workforce education, distribution and capacity.

There are other well publicized examples of countries striving toward hepatitis C elimination through treatment scale up. After two years of treatment access in Iceland, 80-85% of the population of around 1000 people living with hepatitis C have been cured.²⁰ In the country of Georgia, approximately 34,000 people have started treatment after two years out of 46,000 diagnosed and 150,000 people living with hepatitis C.²¹ These country-level programs emphasize the need for high rates of diagnosis, linkage to care *and* treatment uptake in order to achieve global elimination targets.

Maintaining high levels of hepatitis C treatment requires high levels of hepatitis C testing to ensure sufficient new cases are detected and linked to care. The WHO 2030 elimination targets call for 90% of hepatitis C-infected people to be diagnosed.²² Currently many people infected with hepatitis C do not know they have the virus, and even amongst those who are diagnosed many are not linked to care. Many groups have demonstrated attrition along the testing stages of the care cascade globally.²³⁻²⁶ Even in Australia, where 70-85% of people with hepatitis C infection are estimated to have been tested for hepatitis C antibodies in the past, there is a substantial decline in the HCV RNA testing to confirm chronic infection (estimated at 45-50% of those living with chronic HCV).^{5,27} National modelling shows that to meet the elimination targets, there will need to be a substantial increase in hepatitis testing (both antibody and RNA) to feed into treatment uptake.^{28,29}

1
2 Simplifying the care cascade and reducing the numbers of appointments patients have to
3 attend to initiate treatment could greatly reduce loss to follow up and increase the numbers of
4 people achieving cure.³⁰ In order to improve the care cascade locally, national strategies are
5 now focusing on frequent, repeated HCV RNA testing (at least annually) in key risk
6 populations as a mechanism to re-engage and link people to care. Point of care HCV
7 diagnostic tests – which have been licensed for use overseas but are awaiting approval in
8 Australia – will also play an important role in offering accessible, regular testing for
9 populations at higher risk of infection. They have been piloted in Australian drug and alcohol
10 settings, emergency departments, community health service, and prisons.^{16,28} Since testing
11 uptake is not captured in prescribing datasets, but may be recorded in other health service
12 databases, future data linkage research to overlay testing and prescribing trends would greatly
13 help understand gaps in our care cascade caused by insufficient testing.

14
15 Allowing general practitioners to prescribe DAA to maintain ongoing treatment uptake is
16 essential. The data presented in this study demonstrate that GP prescribing has increased from
17 the pre-DAA era but stabilising at around 1900 treatments per quarter over the last 12
18 months. The initial high uptake in treatment, with the high proportion of scripts written by
19 specialists likely reflects the large pool of patients waiting for treatment in tertiary settings
20 following a period of lower than average treatment from 2013-2015. The issue now is the
21 rapid decline in treatment after the initial surge. GP prescribing appears to be particularly
22 important outside of metropolitan where they are providing nearly half of all care. If GPs
23 maintain current treatment numbers, combined with treatment in other sectors then
24 Australia's elimination response will remain on target.³¹ However if GP prescribing was to
25 fall after a year or two (as occurred with the specialists) Australia may struggle to reach its
26 elimination goals. There are over 27,000 GPs practicing in Australia, compared with fewer
27 than 700 hepatologists.³² Given that fewer than 10,500 general practice issued DAA
28 prescriptions (Table 1), most GPs must have no experience prescribing hepatitis C DAAs.
29 Further research is needed to understand why and examine how to support GPs to increase
30 their prescribing numbers.

31
32 In Australia, as with most high-income countries, the group most affected by HCV are
33 PWID,³³ yet this population remains the least-diagnosed, lowest-engaged and least-
34 treated.^{34,35} Rapidly and substantially increasing the numbers of PWID treated, engaged and
35 retained in care is critical to reducing HCV transmission and burden.⁸ A further advantage of

1 supporting non-hepatitis specialists to commence treatment is that they often service opiate
2 substitution therapy, mental health and sexual health services where PWID are
3 disproportionately engaged in care. Currently Australia's overall treatment numbers do not
4 reveal whether sufficient PWID are receiving treatment to more rapidly reduce transmission;
5 it has been estimated that 5000 PWID need to commence treatment each year to meet
6 elimination goals.¹³ Previous models of HCV epidemics where transmission is predominantly
7 due to unsafe injecting drug use suggest that treating currently-injecting PWID will lead to
8 significant reductions in HCV incidence and liver-related morbidity.^{13,36,37} However these
9 models clearly show that even with unlimited and unrestricted access to HCV treatment, as is
10 the case in Australia, additional interventions to target PWID and enhance their access to
11 HCV diagnostic testing, pre-treatment assessment, and retention in care are required to
12 achieve elimination targets.⁸

13
14 The Eliminate C Partnership is a system wide response to the challenge in linking PWID to
15 care. It is an Australian project involving government, researchers, health services and civil
16 society to support new models of care. Its key purpose is to increase treatment access for key
17 populations through health promotion and community engagement programs, systems change
18 for rapid testing and re-testing, and providing nursing and peer support to clinics with high
19 caseloads of key affected populations. Community-based care, pharmacist-led care and nurse-
20 led treatment are all being developed as methods of increasing testing and linkage to care.³⁸
21 They have informed revisions to guidelines in Australia, where community care models for
22 PWID are now considered routine.¹⁵ Prescriber awareness of testing and linkage to care is
23 being supported through the Eliminate C Partnership, national education programs provided
24 by professional societies and community organisations, and state based education and
25 training consortia funded by government. Interventions to increase testing in general practice
26 including incentives, peer support, clinical audit tools, and active case finding of those
27 previously tested are being tested at a local service level.

28
29 National prescribing data in Australia has limitations. First, there is some delay in reporting
30 prescription data, meaning some treatment commencements might have occurred up to a few
31 weeks prior to reporting, and hence underestimate the most recent quarters' data. However,
32 these reporting delays are likely to remain similar over time and therefore are unlikely to
33 have affected the trends reported here. Secondly, given privacy considerations, individual
34 patient level data is not released in the entire dataset. Granular data on exact prescription by
35 provider and geographic area, including patient demographics, is collected but censored

before release. This limits any analysis based on individual predictors of treatment commencement, including the ability to accurately determine the number of people with cirrhosis, comorbidities, drug use, PWID, prisoners or HIV-coinfection receiving treatment.³⁹ Thirdly, prescribing data is not linked to clinical outcome data in Australia at present. This represents a missed opportunity to definitively and directly report real world cure rates and any changes in epidemiology brought about by treatment. Moves are underway to address this gap in monitoring through enhanced surveillance systems and linked cohorts; nevertheless, prescription data collected by the national government is likely to remain outside that surveillance system. Finally, the data count all treatment initiations as separate individual cases and cannot count retreatment as yet. Modelling from the USA projects the need for retreatment in around 8% of all individuals each year.⁴⁰ This might falsely inflate the estimates of individuals treated, but given the data is largely from year one, after allowing for treatment and follow up time, the number of people being re-treated with DAAs is probably very small to date. Notwithstanding these inherent limitations, this analysis allows for the formation of hypothesis around service gaps, and importantly, provides context and justification for future well-designed cohorts or interventional studies to better understand and enhance treatment access.

In conclusion, rapid treatment uptake over the first year in Australia was very high, although perhaps not unexpectedly, was not sustained. The challenge for Australia, and other similar countries, is to ensure that following the initial enthusiasm for treatment, that treatment numbers are sustained at a level sufficient to achieve elimination. Key factors in ensuring this occurs includes removing all unnecessary barriers to testing and care, and allowing and encouraging general practitioners to prescribe treatment. It is also critical that there are high levels of engagement and treatment amongst people in high risk groups where ongoing transmission is occurring. Experience suggests this will not happen by chance and a focussed effort is required to ensure treatment scale up for these groups to the levels identified in the elimination models. Our observations have international significance as other countries move towards unrestricted treatment access. Treatment subsidies are necessary but will be insufficient alone to reach the WHO elimination targets. Universal treatment needs to be combined with enhanced prevention, testing, linkage to care, and treatment programs that are easily accessible to all people with chronic hepatitis C infection.

DECLARATION OF INTERESTS

Burnet Institute acknowledges support from the Victorian Government Operational Infrastructure Fund.

JD, NS, RSD, AP, MH: Burnet Institute receives unrelated investigator-initiated research grants from Gilead Sciences, AbbVie, Merck/MSD, and Bristol Myers Squibb.

JD: received honoraria for speaking from Gilead Sciences, Merck/MSD, Bristol Myers Squibb, and Abbvie.

AT: received research grant support from Merck/MSD, Bristol-Myers Squibb, Gilead Sciences; is a consultant/advisor to Gilead Sciences, Abbvie, BMS, Merck/MSD, Roche Pharmaceuticals, Janssen-Cilag; received honoraria for speaking from Abbvie, Merck/MSD, Roche Pharmaceuticals, Bristol-Myers Squibb

ABBREVIATIONS

HCV, Hepatitis C virus; DAA, direct acting antiviral therapy; PEG-IFN, pegylated-interferon; RBV, ribavirin; PWID, people who inject drugs

REFERENCES

1. Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *The Lancet Gastroenterology & Hepatology* 2017; **2**(3): 161-76.
2. World Health Organization. Global Hepatitis Report 2017. Geneva: World Health Organisation; 2017.
3. Sievert W, Razavi H, Estes C, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. *Journal of Gastroenterology and Hepatology* 2014; **29**: 1-9.
4. Hepatitis C Sub-Committee; Ministerial Advisory Committee on AIDS Sexual Health and Hepatitis. Hepatitis C Virus Projections Working Group: Estimates and projections of the hepatitis C virus epidemic in Australia 2006. Sydney Australia: UNSW, 2006.
5. Kirby Institute. 2016 Annual Surveillance Report of HIV, Viral Hepatitis, STIs. Sydney: UNSW; 2016.
6. Aitken CK, Agius PA, Higgs PG, Stoove MA, Bowden DS, Dietze PM. The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs. *Epidemiol Infect* 2017; **145**(4): 796-801.
7. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; **378**(9791): 571-83.

8. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology* 2013; **58**(5): 1598-609.
9. Hellard M, Rolls DA, Sacks-Davis R, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. *Hepatology* 2014; **60**(6): 1861-70.
10. Vickerman P, Martin N, Hickman M. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. *Drug and alcohol dependence* 2011; **113**(2-3): 83-7.
11. Scott N, Hellard M, McBryde E. Modelling hepatitis C virus transmission among people who inject drugs: assumptions, limitations and future challenges. *Virulence* 2016; **7**(2): 201-8.
12. Hellard M, Jenkinson R, Higgs P, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. *Med J Aust* 2012; **196**(10): 638-41.
13. Scott N, McBryde E, Thompson AJ, Doyle JS, Hellard ME. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. *Gut* 2017; **66**(8): 1507-15.
14. Scott N, Thompson AJ, Iser DM, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. *J Gastroenterol Hepatol* 2016; **31**(4): 872-82.
15. Gastroenterological Society of Australia. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Melbourne: GESA; 2016.
16. Pedrana AE, Sacks-Davis R, Doyle JS, Hellard ME. Pathways to the elimination of hepatitis C: prioritising access for all. *Expert Rev Clin Pharmacol* 2017; **10**(10): 1023-6.
17. Razavi H. Modeling for policy change: Policy tools for HepC elimination. World Hepatitis Summit. Sao Paulo, Brazil 2017.
18. Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS): Volume 5 - Remoteness Structure. Canberra: ABS; 2011.
19. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden. *J Viral Hepat* 2014; **21**(Suppl 1): 1-4.
20. Tyrfingsson T, Runarsdóttir V, Hansdottir I, et al. Marked reduction in the prevalence of HCV among PWID during 2nd year of the Treatment as Prevention (TraP HepC) programme in Iceland. *J Hepatol* 2018; **68**: S52.

21. Tsertsvadze T, Gamkrelidze A, Chkrtishvili N, et al. Hepatitis C care cascade in the country of Georgia after 2 years of starting national hepatitis C elimination programme. *J Hepatol* 2018; **68**: S53.
22. World Health Organization. Draft global health sector strategy on viral hepatitis, 2016-2021 - the first of its kind. 2015; (7/12/2015).
23. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. *N Engl J Med* 2013; **368**(20): 1859-61.
24. Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. *Hepatology* 2016; **63**(4): 1090-101.
25. Wade AJ, MacDonald DM, Doyle JS, et al. The cascade of care for an Australian community-based hepatitis C treatment service. *PLoS One* 2015; **10**(11): e0142770.
26. Chen DS, Hamoudi W, Mustapha B, et al. Strategies to manage hepatitis C virus infection disease burden-Volume 4. *J Viral Hepat* 2017; **24 Suppl 2**: 44-63.
27. Snow K, Scott N, Clothier HJ, MacLachlan JH, Cowie B. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis. *Aust N Z J Public Health* 2017; **41**: 193-8.
28. Scott N, Doyle JS, Wilson DP, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. *Int J Drug Policy* 2017; **47**: 107-16.
29. Scott N, Sacks-Davis R, Pedrana AE, Doyle JS, Thompson AJ, Hellard ME. Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings. *J Viral Hepat* 2018; **25**(12): 1472-80.
30. Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. *The International journal on drug policy* 2017; **47**: 34-46.
31. Kwon JA, Dore GJ, Grebely J, et al. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. *J Viral Hepat* 2018: Sep 29. doi: 10.1111/jvh.13013.
32. Australian Institute of Health and Welfare. National Health Workforce Data Set: Medical practitioners 2015. Canberra: AIHW; 2015.
33. Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. *The Lancet Global health* 2017; **5**(12): e1208-e20.

34. Snow K, Scott N, Clothier HJ, MacLachlan JH, Cowie B. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis. *Australian and New Zealand journal of public health* 2016.
35. Sublette VA, Smith SK, George J, McCaffery K, Douglas MW. The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. *Psychology & health* 2015; **30**(8): 987-1004.
36. Martin NK, Foster GR, Vilar J, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. *Journal of viral hepatitis* 2015; **22**(4): 399-408.
37. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: World Health Organization, 2016.
38. Radley A, Tait J, Dillon JF. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. *Int J Drug Policy* 2017; **47**: 126-36.
39. Lin M, Kramer J, White D, et al. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. *Alimentary pharmacology & therapeutics* 2017; **46**(10): 992-1000.
40. Chhatwal J, Chen Q, Ayer T, et al. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. *Alimentary pharmacology & therapeutics* 2018; **47**(7): 1023-31.

TABLES

Table 1: Hepatitis C direct-acting antiviral treatment commencement in Australia per quarter by provider type (% of all prescriptions)

	General practitioner	Hepatology/ Infectious Disease specialist	Addiction/ Sexual health specialist	Other medical practitioners	Total per quarter
2016 Q1	387 (9%)	3021 (74%)	510 (12%)	192 (5%)	4110
2016 Q2	2114 (16%)	8248 (63%)	2110 (16%)	637 (5%)	13109
2016 Q3	2173 (24%)	4931 (54%)	1673 (18%)	365 (4%)	9142
2016 Q4	1861 (29%)	3119 (48%)	1260 (19%)	276 (4%)	6516
2017 Q1	1979 (32%)	2703 (44%)	1250 (20%)	253 (4%)	6185

2017 Q2	1964 (37%)	2037 (38%)	1116 (21%)	203 (4%)	5320
Total by prescriber	10478 (24%)	24059 (54%)	7919 (18%)	1926 (4%)	44382

Figure 1: Hepatitis C treatment commencement per quarter in Australia by treatment regimen (interferon based versus direct-acting antiviral) from 2013-2017

Figure 2: Hepatitis C direct-acting antiviral treatment commencement in Australia by prescriber over time since universal access from 2016

Figure 3: Hepatitis C direct-acting antiviral treatment commencement in Australia by geographic area over time 2016-2017

apt_15210_f1.png

apt_15210_f2.png

apt_15210_f3.png

apt_15210_f4.png

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Doyle, JS;Scott, N;Sacks-Davis, R;Pedrana, AE;Thompson, AJ;Hellard, ME;Dietze, P;McBryde, E;Sievert, W;Stoove, M;Higgs, P;Petrie, D;Vickerman, P

Title:

Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia

Date:

2019-05-01

Citation:

Doyle, J. S., Scott, N., Sacks-Davis, R., Pedrana, A. E., Thompson, A. J., Hellard, M. E., Dietze, P., McBryde, E., Sievert, W., Stoove, M., Higgs, P., Petrie, D. & Vickerman, P. (2019). Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 49 (9), pp.1223-1229. <https://doi.org/10.1111/apt.15210>.

Persistent Link:

<http://hdl.handle.net/11343/285640>